Oral News and Research

RSS

New oral drug reduces menstrual bleeding for women with common uterine tumors

A new oral drug significantly reduced menstrual bleeding for women with the most common gynecologic tumors in the United States - benign tumors that disproportionately affect African-Americans, an international clinical trial found.

9 Nov 2018

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

A phase 2 clinical trial led by Stephanie N. Taylor, MD, Professor of Medicine and Microbiology in the Section of Infectious Diseases at LSU Health New Orleans School of Medicine, has found that a new antibiotic effectively treats uncomplicated urogenital and rectal gonorrhea infections in a single oral dose.

9 Nov 2018

Report: Persistent inequities may hamper progress to stop child pneumonia and diarrhea deaths

Globally, pneumonia and diarrhea together led to nearly one of every four deaths that occurred in children under five years of age in 2016.

9 Nov 2018

New study does not support hypertensive effect from urate elevation

A study from a group of Massachusetts General Hospital investigators may reduce the concern that elevating levels of urate, an approach being investigated to treat several neurodegenerative disorders, could increase the risk of hypertension.

8 Nov 2018

Breastmilk and saliva mixtures regulate oral microbiome of newborn babies

A study led by Dr Emma Sweeney and Adjunct Associate Professor Christine Knox, from QUT's Institute of Health and Biomedical Innovation, with colleagues at the University of Queensland, showed that the growth of some microbes was inhibited for up to 24 hours following breastmilk and saliva mixing.

8 Nov 2018

Oral antibiotic shows promise to cure uncomplicated gonorrhea

An investigational oral antibiotic called zoliflodacin was well-tolerated and successfully cured most cases of uncomplicated gonorrhea when tested in a Phase 2 multicenter clinical trial, according to findings published today in the New England Journal of Medicine.

8 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Experts identify barriers to using stroke-preventing anticoagulants in Canada

International guidelines recommend direct oral anticoagulants over warfarin to prevent stroke for most patients with atrial fibrillation.

5 Nov 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

Routine mouth cancer screens could save lives

The Head and Neck Cancer Foundation is calling all Brits to ask their dentists to conduct mouth cancer screens at their next appointment. This should be routinely included within the price of a dental check-up and should take no more than one minute.

2 Nov 2018

Researchers find a class of drug that could be promising treatment for uveitis

Ocular inflammation uveitis is a serious disease that can destroy eye tissue and cause irreversible blindness.

2 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Exploring potential health risks of microplastic particles for humans

The Austrian Federal Environment Agency and the Medical University of Vienna have presented the first preliminary results of a pilot study on microplastics (microplastic particles) in humans.

1 Nov 2018

A fully human cell culture system for growing skin keratinocytes

Breakthrough research to culture human skin cells called keratinocytes to produce skin grafts has been published by a team of researchers from Duke-NUS Medical School and the Singapore General Hospital.

31 Oct 2018

Atopic dermatitis found to be highly prevalent among adults in the U.S.

As many as 16.5 million adults in America suffer from a skin disease known as atopic dermatitis, an inflammatory disease that results in red, itchy skin.

30 Oct 2018

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Experimental vaccine shows promise to protect stroke survivors from blood clots

A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood clots, without increasing the risk of serious bleeding or triggering an autoimmune response, according to new research in the American Heart Association's journal Hypertension.

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Tooth loss linked to malnutrition risk in older adults

Older adults are at risk for both impaired oral health and malnutrition, according to a study by Rutgers University researchers.

25 Oct 2018

Head and neck cancer survivors more likely to commit suicide

Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

25 Oct 2018

Oral News and Research

New oral drug reduces menstrual bleeding for women with common uterine tumors

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

Report: Persistent inequities may hamper progress to stop child pneumonia and diarrhea deaths

New study does not support hypertensive effect from urate elevation

Breastmilk and saliva mixtures regulate oral microbiome of newborn babies

Oral antibiotic shows promise to cure uncomplicated gonorrhea

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Experts identify barriers to using stroke-preventing anticoagulants in Canada

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Routine mouth cancer screens could save lives

Researchers find a class of drug that could be promising treatment for uveitis

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Exploring potential health risks of microplastic particles for humans

A fully human cell culture system for growing skin keratinocytes

Atopic dermatitis found to be highly prevalent among adults in the U.S.

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

Experimental vaccine shows promise to protect stroke survivors from blood clots

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Tooth loss linked to malnutrition risk in older adults

Head and neck cancer survivors more likely to commit suicide

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News